The agents and uses mentioned below are investigational and have not been approved by the US Food and Drug Administration (FDA) for the uses under investigation. No conclusions regarding safety and efficacy should be drawn for such agents and uses.
The rare blood disorders pipeline has a scope beyond hemophilia, including investigational therapies includes investigational therapies for warm autoimmune hemolytic anemia (wAIHA) and sickle cell disease (SCD).